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SCIENTIFIC OPINION 
Scientific Opinion on the safety of “rapeseed protein isolate” as a Novel 
Food ingredient 1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver a scientific opinion on the safety of a “rapeseed protein isolate” 
(Isolexx
TM
) as a novel food ingredient (NF) in the context of Regulation (EC) No 258/97. The NF is an aqueous 
extract with at least 90 % protein, isolated from rapeseed press cake originating from so-called canola varieties. 
The applicant intends to market the NF for the same food products, at similar concentrations and for 
corresponding purposes, as soy protein isolates. Total protein intake of "heavy" adult consumer may be 
estimated as the mean + 2 SD, i.e. 2.2 g/kg bw per day. The age group of 4 - 6 years is estimated to have the 
highest protein intake on a per kg bw basis with a mean and 95th percentile intake of up to 3 and up to 4.73 g/kg 
bw per day, respectively. A significant part of these estimated intakes could come from rapeseed protein. The 
Panel considers that the risk of sensitisation to rapeseed cannot be excluded and that it is likely that rapeseed 
trigger can allergic reactions in mustard allergic subjects. The biological value of rapeseed and soy protein, 
determined by the PDCAAS, appears to be similar. The Panel notes the source and nature of the novel food, the 
absence of a nutritional disadvantage at the proposed uses and use levels, the low concentrations of potentially 
adverse components in the NF, and the absence of toxicologically relevant effects in subchronic studies with rats 
conducted with rapeseed protein isolates with similar compositions. The Panel concludes that rapeseed protein 
isolate is safe under the proposed uses and use levels. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on the safety of a “rapeseed protein 
isolate”. The novel food (NF) rapeseed protein isolate (IsolexxTM) is an aqueous protein-rich extract 
from rapeseed press cake originating from the two Brassicaceae species, Brassica napus L. and 
Brassica rapa L., both so-called canola varieties. Canola varieties are characterised by their low 
content of erucic acid (≤ 2 % by mass in the oil) and glucosinolate content of below 30 μmol/g in the 
air-dried, oil-free meal. The albumin napin and the globulin cruciferin, are the two major storage 
proteins and represent the majority of proteins in rapeseed. The results from batch testing of twelve 
production batches showed compliance with the specifications as proposed by the applicant. The 
Panel considers that the information provided on the composition, specifications and stability and 
production process of the NF does not raise safety concerns. 
The applicant intends to market the NF essentially for the same food products, at similar 
concentrations and for corresponding purposes, as soy protein isolates, namely: a) as a source of 
protein, for example, in meal replacements (formula diets), protein drinks (including “dairy 
analogues”), nutrition bars, soups and soup mixes, breakfast cereals, plant protein products (meat 
analogues), and b) for improving the texture of, for example, bakery products, chilled or frozen 
processed meat products (such as patties), pasta, desserts, and other foods and in food supplements. 
The NF is not intended for use in infant formulae and follow-on formulae. The applicant provided 
intake estimates based on the intended uses and on protein intake data provided in the Scientific 
Opinion on Dietary Reference Values for protein published by the EFSA NDA Panel in 2012. Total 
protein intake of "heavy" adult consumer may be estimated as the mean + 2 SD, i.e. 2.2 g/kg bw per 
day. The age group of 4 - 6 years is estimated to have the highest protein intake on a per kg bw basis 
with a mean and 95th percentile intake of up to 3 and up to 4.73 g/kg bw per day, respectively. A 
significant part of these intake estimates could come from rapeseed protein. 
According to data provided by the applicant, the levels of compounds contained in the NF such as 
erucic acid, glucosinolates, AITC and polyphenols are either below detection limits or below levels 
which may raise concerns. In addition, the applicant provided two publications on two 13-week 
toxicity studies in rats which studied a cruciferin protein rich isolate and a napin protein rich isolate 
from canola quality rapeseed produced by another manufacturer. Both products contained erucic acid, 
total glucosinolates, AITC, total phytates, and phenolics at similar concentrations as the NF. The 
Panel notes that in the study with cruciferin protein isolate, no treatment-related effects were noted, 
whereas in the study with napin protein isolate lower feed intake associated with reduced body weight 
gain and a reduced feed efficiency was observed, which may be caused by a low palatability and in 
part by an antinutritional effect inducing discomfort and consequently a conditioned taste aversion. 
Several Member States expressed concerns with regard to a potential risk of allergenicity of rapeseed 
proteins in general, and with regard to potential cross-allergenicity of rapeseed proteins with proteins 
of other Brassicacae, particularly of mustard. The applicant has not carried out any studies to 
determine the potential allergenicity of the rapeseed protein isolate to which the application relates. 
Food allergy to rapeseed (Brassica rapa L.) and oilseed rape (Brassica napus L.) has been reported to 
occur, as evidenced by studies in humans. In a study, 11 % (206/1887) of atopic Finnish children with 
suspected food allergies who were screened using skin prick tests showed sensitivity to seeds of 
Brassica rapa L. and/or Brassica napus L. A subsequent challenge test confirmed that 89 % of 
sensitised children were allergic. In another study by the same authors, a group of homologous 
proteins, 2S albumins or napins, were identified as new possible food allergens. The authors 
considered that even the smallest quantities of protein residues present in refined or cold-pressed 
rapeseed oils might be sufficient to produce sensitisation. There are also indications of cross reactivity 
between rapeseed and other foods. According to the authors, the cross-reactivity between mustard and 
rapeseed flours could be explained by the high amino acid sequence homology between the two 
proteins. Mustard allergy has been reported in France and has also been investigated also in Spain,  
including studies on cross-reactions within Brassicaceae. One study showed that seed storage proteins 
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of various members of Brassicaceae, including mustard, have highly homologous molecular level 
structures and present risks of allergic reactions and cross-reactions in sensitised individuals.  
The Panel concludes that the risk of sensitisation to rapeseed, as well as the risk of cross-reactivity in 
subjects allergic to mustard, cannot be excluded.  
The NF, a canola quality rapeseed protein isolate, shares many properties with soy protein isolates, 
which are isolated in a similar way from the press cake remaining from soy oil production. The 
macronutrient composition of the NF is similar to commercially available soy protein isolates. The 
biological value of rapeseed and soy protein, determined by the PDCAAS, appears to be similar. 
The Panel notes that people may consume up to 2.2 g protein/kg bw per day, of which a significant 
part may come from rapeseed protein. The Panel also notes that some subgroups of the population, 
such as sportspeople, may consume even higher amounts of protein. Only in an extreme scenario, in 
which “high consumers”, such as vegans would consume rapeseed protein isolates as their sole source 
of protein, can an antinutritional effect not be excluded. The Panel considers that such a worst case 
scenario is unrealistic, and it would imply the consumption of an unbalanced diet, which is generally 
not recommended.  
The Panel considers that the risk of sensitisation to rapeseed cannot be excluded and that it is likely 
that rapeseed trigger can allergic reactions in mustard allergic subjects.  
The Panel notes the source and nature of the novel food, the absence of a nutritional disadvantage at 
the proposed uses and use levels, the low concentrations of potentially adverse components in the NF, 
the extended use of rapeseed press cake in farm animals, and the absence of toxicologically relevant 
effects in subchronic studies with rats of other rapeseed protein isolates with similar compositions. 
The Panel notes that based on the results of one of the rat studies, the possibility of an antinutritional 
effect caused by the novel food at high intakes, i.e. if rapeseed protein isolate was the main protein 
source in the diet, cannot be excluded.  
The Panel concludes that rapeseed protein isolate is safe under the proposed uses and use levels. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 25 June 2012, Bioresco Ltd., on behalf of the company Helm AG, submitted a request under 
Article 4 of the Novel Food Regulation (EC) N° 258/97 to place on the market “rapeseed protein 
isolate” as a novel food ingredient. 
On 17 September 2012, the competent authorities of Ireland forwarded to the Commission their initial 
assessment report, which came to the conclusion that rapeseed protein isolate may be placed on the 
market.  
On 4 October 2012, the Commission forwarded the initial assessment report to the other Member 
States. Several of the Member States submitted comments or raised objections. 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 
 The specification should be extended to include limit values for the undesirable compounds: 
erucic acid, allyl isothiocyanate and phenolic compounds such as tannin and sinapin. The 
respective analytical methods must be properly described and validated. 
 The protein fraction should be analysed in more detail. The identity of the different (soluble) 
proteins present in the novel ingredient should be analysed, for example by HPLC analysis. 
 The carbohydrate fraction should be clarified since the ultracentrifugation step is intended to 
remove carbohydrates. Direct analysis of the carbohydrates would give assurance that there are no 
low-molecular proteins present in this fraction.  
 Considering the potential impact of phytates on micronutrient absorption, data from batch testing 
should be provided to demonstrate that phytate levels are consistently within the specified limits. 
 The absence of butane (used for the oil extraction) in the final product should be demonstrated.  
 Information on the content of lead, cadmium and aluminium is lacking. 
 Information should be provided whether phytic acid is completely broken down to inositol by the 
addition of phytase during the manufacturing process. 
 It is not appropriate to compare glucosinolates present in the novel food ingredient with those in 
sprouts since they show different characteristics. 
 The application dossier does not contain data on the stability and shelf life of the product, or any 
information regarding process quality management. 
 Accreditation of the test laboratories issuing test reports is not apparent. Accreditation should be 
according to an internationally-recognised system for analysing food.  
 The production process is insufficiently described, including time between primary extraction by 
mechanical pressure and subsequent treatment (with respect to potential fungal contamination and 
mycotoxin production), level of detail of the ultracentrifugation step, excipients used for the 
atomisation. 
 The figure given for the potential intake of the novel ingredient is only a very rough estimate 
based on a series of assumptions. A more refined intake estimate for the intended target 
populations, including children, should be provided on the basis of the maximum levels of 
enrichment and a comprehensive list of foods to which the novel ingredient may be added. 
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 The extent to which consumption of the novel protein preparation might cause allergic reactions in 
susceptible individuals has been insufficiently investigated. Allergenic properties of rapeseeds 2S 
albumins have been described in the literature (Monsalve et al., 1997). Moreover, OECD's revised 
consensus document on compositional considerations for new varieties of low erucic acid rapeseed 
(canola) reports the publication of studies investigating the potential for Brassica rapa L. and 
Brassica napus L. to be food allergens in children (OECD, 2011).  
 Studies cited by the applicant and the high degree of homology between mustard proteins and 
rapeseed proteins point to cross-reactivity between rapeseed and mustard or allergens associated 
with seeds of other plants of the Brassicaceae family used in the production of mustard. Unlike 
mustard which is generally used in small amounts as a condiment, exposure to rapeseed protein is 
likely to be far more widespread as it is intended to be incorporated into a range of foods, and 
allergy is therefore of more concern.  
 The applicant should provide evidence, based on clinical studies, demonstrating the safety and 
digestibility of the product to which the application relates.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety 
Authority is asked to carry out the additional assessment for “rapeseed protein isolate” as a novel food 
ingredient in the context of Regulation (EC) N° 258/97. 
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific 
nature in the comments raised by the other Member States. 
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ASSESSMENT 
In accordance with Commission Recommendation 97/618/EC, “rapeseed protein isolate” (IsolexxTM) 
has been allocated to Class 2.1, i.e. foods or food ingredients that are „complex novel food from non-
GMO sources. The source of the novel food has a history of food use in the Community‟. The 
assessment of the safety of this novel food ingredient is based on data supplied in the original 
application, the initial assessment by the competent authority of Ireland, the concerns and objections 
of the other Member States, and the responses of the applicant. The data are required to comply with 
the information required for the novel foods of Class 2.1, i.e. structured schemes I, II, III, IX, XI, XII 
and XIII of the Commission Recommendation 97/618/EC. In the text, these structured schemes are 
listed in nine sections. This assessment only concerns risk that might be associated with consumption, 
and is not an assessment of the efficacy of rapeseed protein isolate (Isolexx
TM
) with regard to any 
claimed benefit. 
1. SPECIFICATION OF THE NOVEL FOOD (NF) 
The novel food (NF) rapeseed protein isolate (Isolexx
TM
) is an aqueous protein-rich extract from 
rapeseed press cake originating from the two Brassicaceae species, Brassica napus L. and Brassica 
rapa L., both so-called canola varieties. Canola varieties are characterised by their low content of 
erucic acid (≤ 2 % by mass in the oil) and glucosinolate content of below 30 μmol/g in the air-dried, 
oil-free meal (OECD, 2011). The specifications of the NF provided by the applicant are shown in 
Table 1. The NF will be referred to as “rapeseed protein isolate” in the following assessment. 
Table 1:  Specifications of the NF “rapeseed protein isolate”, as proposed by the applicant 
Parameters Limit values 
(a)
 Methods 
Protein (N × 6.25) ≥ 90 % AOCS Ba 4e-93 
Soluble protein ≥ 85 % Roe et al. (1990) 
Moisture ≤ 7 % AOCS Ba 2a-38 
Carbohydrates ≤ 7 % By difference (b) 
Fat < 2 % AOCS Ba 3-38 
Ash ≤ 4 % AOCS Ba 5a-49 
Fibre ≤ 0.5 % AOCS Ba 6-84 
Total glucosinolate ≤ 1 mmol/kg (450 mg/kg) 
Method of the Canadian Grain Commission 
(Duan and MacGregor, 1981) 
Total phytate ≤ 1.5 % Colorimetric method (Gao et al., 2007) 
Lead ≤ 0.5 mg/kg Atomic absorption(c) 
Aerobic bacteria count ≤ 10 000 cfu/g MFHPB-18 
E. coli negative/10 g MFHPB-34 
Salmonella negative/25 g MFHPB-20 
Total coliform count ≤ 10 cfu/g MFHPB-34 
Yeast and mold count  ≤ 100 cfu/g MFHPB-23 
(a): Based on dry matter 
(b): 100 % - [protein (as is) % + moisture % + fat % + ash % + fibre %] 
(c): Alternatively, ICP-MS may be applied   
The NF is a white to off-white, spray dried powder of which more than 90 % passes a US 80 mesh. It 
has a specified protein content of at least 90 %, with a minimum soluble protein content of at least 
85 %. Upon request from EFSA, the applicant provided more detailed data on the protein composition 
of the NF. As determined by gel permeation chromatography, the product is composed of two major 
fractions: 60-65 % globulin (250 kDa) and 30-35 %  albumin and other minor proteins (10-30 kDa). 
The albumin napin and the globulin cruciferin, are the two major storage proteins and represent the 
majority of proteins in rapeseed (Wu and Muir, 2008). 
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The applicant provided results of the composition of twelve production batches, analysed by an 
external laboratory (Appendix).  
According to the applicant, the concentration of glucosinolates is at or below the detection limit 
(0.1 mmol/kg), which is supported by the results from batch testing. The concentration of allyl 
isothiocyanate (AITC) is limited by the specification limit given for glucosinolates. 
According to the applicant, there is no need to add analytical data on erucic acid to the specification. 
The applicant justified the omission by the low content of erucic acid of canola quality rapeseed, the 
production process which reduces the oil fraction in the NF to a maximum of 2 %, and to the batch 
testing of the NF which showed that the level of erucic acid was below the limit of detection (0.1 % in 
the fat fraction). The Panel agrees with these arguments. 
The Panel notes that the use of canola varieties limits the concentrations of both, thio-glucosinolates 
and thus of AITC, as well as of erucic acid (OECD, 2011). 
Total phytates make up less than 1.5 % according to the batch testing.  
The concentrations of “total phenolics” (expressed in gallic acid equivalents, extraction with 
water:methanol (50:50), analysis by the Folin-Ciocalteu, detection limit at 50 mg/kg) and of sinapin 
(by NMR) in the analysed batches were below 1.6 g/kg and 0.5 g/kg NF, respectively (Appendix). 
A limit value for lead is set in the specification. Following comments from Member States, the 
applicant referred to analyses of four batches, which included lead, cadmium and aluminium analyses. 
The values ranged from < 0.01-0.02 ppm for Pb, 0.16-0.28 ppm for Cd and 7.5-12 ppm for Al. For Pb 
and Cd, the observed values are within the levels that typically apply to foods
4
 (on an anhydrous 
basis). Upon request from Member States and EFSA regarding the high content of 75 ppm Al reported 
initially in one batch of the NF, the applicant clarified that this high value resulted from a transcription 
error from the laboratory report, and provided the original analytical report where an Al content of 
7.5 ppm was reported. The applicant also provided analytical results of nine additional batches of the 
NF, where the Al content was found to be consistently below 10 ppm (range: 1.1-9.8 ppm). The Panel 
notes that maximum permitted levels of Al have not been established in EU food law. Assuming a 
high intake scenario of about 1.1 g NF/kg bw and day for adults (i.e. about 50 % of the high protein 
intake scenario, see Section 4) and a content of 10 ppm Al, the daily intake resulting from the 
consumption of the NF would amount to 0.77 mg Al per day (5.4 mg Al per week). EFSA has 
established a weekly tolerable intake level for aluminium from dietary intake at 1 mg/kg body weight 
(bw) per week (EFSA, 2008). 
The applicant also set out the result of analyses on 307 different plant protection agents (pesticides), 
and on dioxins, PAHs and aflatoxins (B1, B2, G1 and G2). None was detectable above the limits of 
detection. The Panel notes that all foods, and hence also novel foods, have to comply with the existing 
food legislation.  
With regard to the absence in the NF of n-butane used for the oil extraction, the applicant notes that n-
butane may be used as a solvent in the production of any foodstuff in compliance with GMP, as per 
Directive 2009/32/EC
5
. The applicant referred to the analyses of six batches of the NF, which showed 
that this extraction solvent was not present at detectable levels (limit of detection: 10 ppm). 
Regarding the stability and shelf-life of the NF, the applicant reported that after removal of the oil 
(typically at 60 °C), the filter cake (moisture content about 8 %) is cooled to ambient temperature. 
Further processing of the NF takes place not more than 8 hours later. The final product is packed in 
                                                     
4  Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in 
food stuffs, OJ L 364, 5-24. 
5  Directive 2009/32/EC of the European Parliament and of the Council on the approximation of the laws of the Member 
States on extraction solvents used in the production of foodstuffs and food ingredients. OJ L 141, 6 June 2009, pp. 3-9. 
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polylined multi paper bags or polylined cardboard boxes and should be stored below 25 °C and at 
60 % relative humidity. The expiry date is 12 months from the data of manufacture. Given the nature 
of the NF, the Panel considers that the NF is generally stable and not susceptible to degradation if 
protected from humidity under the proposed storage conditions and shelf-life.  
The Panel considers that the information provided on the composition, specifications and stability of 
the NF does not raise safety concerns. 
2. EFFECT OF THE PRODUCTION PROCESS APPLIED TO THE NF 
The applicant provided a summary and flow-chart of the production process, which employs 
conventional separation techniques.  
The starting material for the production of the NF is the press cake that remains after cleaned, flaked 
and conditioned non-GM canola-quality rape seeds have been pressed to separate the oil. After milling 
to reduce particle size, the press cake may be extracted with n-butane in a stirred extractor to remove 
any remaining oil.  
After completion of the extraction, water is added to displace the remaining solvent. The water 
contains about 300 ppm of a liquid preparation with phytase from Aspergillus niger to digest phytates 
naturally present in rapeseeds (Greiner and Konietzny, 2006; Kumar et al., 2010). Phytase from A. 
niger is included in the Codex Alimentarius Inventory of Processing Aids (CX/FA 09/41/8). In France, 
phytase from a specific strain of A. niger is authorised as a processing aid for use in bread dough. 
According to the applicant, phytase activity could not be detected in the NF. 
The rapeseed meal/water slurry is then freed from any remaining solvent at elevated temperature  
under vacuum. The insoluble components (fibres, proteins) are removed by decantation. The obtained 
supernatant is pasteurised, centrifuged and concentrated by removing the bulk of water, mono- and 
oligosaccharides and other low-molecular weight solutes. Larger soluble polymeric carbohydrates 
such as xylans would remain with the protein fraction. The retentate is spray-dried to yield the 
rapeseed protein isolate.  
The Panel considers that the production process is sufficiently described by the applicant and does not 
raise safety concerns. 
3. HISTORY OF THE ORGANISM USED AS A SOURCE  
Rapeseed is an important oilseed crop in many countries and is considered to be the second most 
abundant source of edible oil in the world. “Canola”, a rapeseed variety with low contents of 
nutritionally undesirable compounds (primarily erucic acid and glucosinolates) was developed in 
Canada in the 1970s and has been widely used in the manufacturing of edible oil and animal feeds 
(OECD, 2011). The development of the “Canola” variety has aided in the development of technologies 
that can be used in the production of food grade items from the canola meal which is the by-product of 
oil extraction. Canola meal contains up to 50 % protein on a dry basis (Uppström, 1995).  
The applicant intends to produce the NF from non-GM Brassica napus L. and Brassica rapa L. 
varieties of canola quality, which are characterised by a low content of erucic acid (≤ 2 % by mass in 
the oil) and glucosinolates (≤ 30 μmol/g) in the air-dried, oil-free meal (OECD, 2011).  
4. ANTICIPATED INTAKE/EXTENT OF THE USE OF THE NF 
The applicant intends to market the NF for addition to the same food products, at similar 
concentrations and for corresponding purposes, as soy protein isolates, namely: a) as a source of 
protein, for example, in meal replacements (formula diets), protein drinks (including “dairy 
analogues”), nutrition bars, soups and soup mixes, breakfast cereals, plant protein products (meat 
analogues), and b) for improving the texture of, for example, bakery products, chilled or frozen 
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processed meat products (such as patties), pasta, desserts, and other foods and in food supplements. 
The NF is not intended for use in infant formulae and follow-on formulae.   
The applicant provided intake estimates based on protein intake data provided by the EFSA Scientific 
Opinion on Dietary Reference Values for protein (EFSA NDA Panel, 2012). In the EU, the average 
protein intakes of adults in absolute amounts range from approximately 67 to 114 g/day in men and 
from 59 to 102 g/day in women. Available data suggest an average intake of 0.8 to 1.25 g/kg bw per 
day for adults. According to the applicant, the total protein intake of adult “high” consumers may be 
estimated 2.2 g/kg bw per day.  
Average protein intake varies in infants and young children from about 29 to 63 g/day. Average daily 
intakes increase with age to about 61-116 g/day in adolescents. In general, males have higher intakes 
than females. Only for a few Member States protein intake data per kg body weight are available. The 
estimated mean intakes vary from ≥ 3 g/kg bw per day in the youngest age groups to approximately 
1.2-2.0 g/kg bw per day in children and adolescents aged 10-18 years. The age group of 4-6 years is 
estimated to have the highest protein intake on a per kg bw basis. In the EU, the highest mean and 95
th
 
percentile protein intake for children of this age group were observed in Italy with 3 and 4.73 g/kg bw 
per day, respectively (EFSA NDA Panel, 2012).  
In the general population, about 75 % of protein intake stems from meat and meat products, grain and 
grain-based products, as well as milk and dairy products (EFSA NDA Panel, 2012). Another 7-8 % is 
ingested with seafood, eggs and egg products. The remaining 18 % of protein intake, corresponding to 
0.15 g/kg bw per day, may in part represent protein isolates such as soy protein isolates which are 
added to processed foods. The latter may represent a higher proportion of the diet of vegans. 
The Panel notes that adult “high” consumers may consume 2.2 g protein/kg bw per day, of which a 
significant part could come from rapeseed protein. However, the Panel also notes that some subgroups 
of the population, such as sports people, may consume even higher amounts of protein.  
5. INFORMATION FROM PREVIOUS EXPOSURE TO THE NF OR ITS SOURCE 
Varieties of rapeseed with low contents of erucic acid and glucosinolates have a significant history of 
safe food use as a source for oil worldwide. The applicant also referred to two already authorised 
rapeseed-derived oil based novel foods (EFSA, 2004a; EFSA, 2005). However, protein from the seed 
material that remains after the removal of the oil has only recently been examined as an alternative 
source of vegetable protein in food. According to the applicant, four distinct rapeseed protein-rich 
ingredients may be placed on the USA market following GRAS notices, including Isolexx
TM
. 
However, according to the applicant rapeseed protein ingredients are currently not consumed to any 
significant degree in the USA.  
6. NUTRITIONAL INFORMATION ON THE NF 
In a study conducted in rats, the NF was provided as the sole dietary protein at levels of 7.5 %, 15 % 
and 30 % (Liebert, 2010, unpublished study report) and true fecal nitrogen (N) digestibility of 93.1 
± 1.9 %, 94.8 ± 1.2 % and 91.1 ± 1.4 % were observed, respectively. True fecal N-digestibility of 
91.9 ± 1.3 % for the NF, 94.9 ± 0.4 % for a soy protein isolate (Dunasoy 90) and 97.4 ± 0.3 % for 
casein were found in a subsequent comparison in rats fed the respective proteins as the sole source of 
dietary protein at levels of ~ 15 %. Another study in rats fed a diet with 15 % canola protein isolate as 
the sole protein source reported true fecal N-digestibilities of 94.8 ± 1.2 % and 91.9 ± 1.3 % in two 
separate experiments (Fleddermann et al.,2013).  
A study performed in humans equipped with an intestinal tube at the terminal ileum and receiving 30 g 
15
N-labelled rapeseed protein isolate from other manufacturers reported a true ileal protein digestibility 
of 84.0 ± 8.8 % (Bos et al, 2007) and another study using the same approach reported true ileal protein 
digestibilities of 91 % and 87 % rapeseed protein in pigs and humans, respectively (Deglaire et al, 
2009).  
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The Panel notes that rat fecal digestibility is not considered as a good model and usually overestimates 
protein digestibility for humans, that results obtained in humans are preferred. 
The applicant provided information on the amino acid composition of four batches of the NF protein 
and compared it with the amino acid composition of four commercial soy protein preparations. The 
amount of lysine was about 15 % higher in soy protein, whereas the amount of sulphur containing 
amino acids (cysteine/cystine plus methionine) was about 65 % higher in the rapeseed protein. The 
values for other amino acids were comparable. According to the data provided by the applicant, the 
levels of lysine and all other essential amino acids in rapeseed protein meet the amino acid scoring 
pattern recommended by the US Institute of Medicines (IOM, 2006). In addition, the applicant 
referred to FAO (1991) reporting similar high protein digestibility (> 95 %) for rapeseed protein and 
soybean protein isolates. Protein-digestibility corrected amino acid scores
6 
 (PDCAAS) were 0.92 for 
soybean protein isolate vs. 0.83 for rapeseed protein isolate, not manufactured by the applicant (FAO, 
1991).  
The Panel notes that it is not satisfactory to compare profiles with other protein. The Panel notes that 
the PDCAAS should be calculated based on recent official reference patterns (WHO, 2007; EFSA, 
2012). Using the most recent amino acid scoring pattern (EFSA NDA Panel, 2012) and a digestibility 
of 85 % from human studies, the PDCAAS of five batches of the NF has been calculated. The mean 
and the range of the PDCAAS of the five batches were 0.98 and 0.92-1.00, respectively, with mainly 
lysine (in four batches) or leucine (one batch) as potentially limiting amino acids. The Panel notes that 
this PDCAAS range is similar to the PDCAAS of soy protein with methionine+cysteine as limiting 
amino acids (EFSA NDA Panel, 2012). Fleddermann et al. (2013) applied the approach in compliance 
with the amino acid scoring pattern proposed by EFSA (EFSA NDA Panel, 2012) on one rapeseed 
protein isolate (called “CPI” in the article) with 4.78 g lysine per 100 g protein produced by the same 
producer of the NF, and the PDCAAS was 86 %.  
In a double-blind cross-over study, Fleddermann et al. (2013) investigated the effect of rapeseed vs. 
soy proteins on plasma amino acid concentrations and N balance. After a three day run-in, 28 healthy 
male subjects consumed 30 g protein dissolved in tomato juice, as follows: Group A: canola protein 
isolate (n = 7), or soy protein isolate (SPI) (n = 7); Group B: canola protein hydrolysate (n = 7), or SPI 
(n = 7). Blood samples were collected at regular intervals up to 8 hours postprandial, and a urine 
sample was collected over 24 hours after ingestion. After a three week wash-out period, a second 
experiment was performed, where the protein sources were crossed within the four 
subgroups. Consumption of canola protein or soy protein led to significant increases in plasma amino 
acids after 62.3 and 83.6 minutes, respectively. Canola protein hydrolysate produced an earlier amino 
acid response compared to canola protein isolate and soy protein isolate, while the total amino acid 
response was comparable between all interventions. No statistical differences were found when 
comparing nitrogen balance of canola protein hydrolysate (0.73 ± 2.48 g N/day), canola protein isolate 
(2.16 ± 2.42 g N/day) and soy protein isolate (2.75 ± 3.41 g N/day (group A) and 1.61 ± 3.23 g N/day 
(Group B)). The Panel notes that the post-prandial kinetic of blood amino acid does not provide a 
suitable criterion to assess protein quality, and that nitrogen balance measured in acute conditions 
traduces the effect of the habitual diet of the subjects more than the quality of Canola protein. 
The Panel notes that the quality of the NF rapeseed protein source measured by the PDCAAS is in the 
range of 92 - 100 %, depending on the batches of the NF protein, that lysine, which is particularly 
sensitive to food treatment, is the main limiting amino acid in the NF, and that the protein digestibility, 
biological value and PDCAAS seem to be highly dependent on the production process and batch-to-
batch/product variation. 
The Panel notes that the range of PDCAAS values calculated for five batches of the NF is not different 
from the value of around 95 % (with methionine + cysteine as limiting amino acids) estimated for soy 
protein. The Panel considers that intake of the NF is not nutritionally disadvantageous compared to 
                                                     
6
  PDCAAS = mg of amino acid in 1 g test protein : mg of amino acid in requirement pattern x true digestibility 
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soy protein isolate at the proposed conditions of use. However, the Panel also notes that due to the 
limiting amino acid lysine, this novel protein source cannot compensate lysine deficiency of cereal-
based diets, in contrast to soy protein which is relatively high in lysine. 
7. MICROBIOLOGICAL INFORMATION ON THE NF 
The Panel considers that the data provided do not raise safety concerns with regard to the 
microbiological quality of the NF. 
8. TOXICOLOGICAL INFORMATION ON THE NF  
The applicant provided references and considerations on the type and amount of undesirable 
compounds contained in the NF.  
With regard to erucic acid, the applicant referred to the Codex Standard 210-1999 for vegetable oils 
intended for human consumption (WHO, 1999), which sets the maximum concentration of erucic acid 
at 2 % of the oil. The applicant also referred to the provisional tolerable daily intake of 7.5 mg/kg bw 
erucic acid set in Australia/NZ (FSANZ, 2003). Considering the source, the production process, the 
specification of the NF (fat content  < 2 %) and the batch testing (erucic acid not detected at a 
detection limit of 0.1 % of total fat), the Panel considers that the concentration of erucic acid in the NF 
is negligible. 
According to the information provided by the applicant, the total level of glucosinolates in the NF is 
typically below the limit of detection (0.1 mmol/kg). According to the applicant, higher levels are only 
rarely found, and would not exceed 0.2 mmol/kg. However, considering the maximum level provided 
for glucosinolates in the specification of the NF (≤ 1 mmol/kg), and assuming a high daily intake 
scenario of e.g. 1.1 g NF/kg bw for adults (i.e. about 50 % of the high protein intake scenario, see 
Section 4), this would result in a maximum intake of ≤ 77 µmol (ca. 40 mg) glucosinolates. According 
to the information provided by the applicant, this is similar to the amount ingested with c. 7 g boiled 
brussels sprouts or 33 g cooked cauliflower. One Member State, as well as the applicant, indicated, 
however, that glucosinates are a heterogenous group of secondary plant metabolites. The major 
glucosinolates found in rapeseed are progoitrin, gluconapin, 4-hydroxyglucobrassicin and 
glucobrassicanapin (Millán et al., 2009). The Panel notes that the scenario above represents a 
conservative scenario. If, as claimed by the applicant and as supported by the batch testing, the level of 
glucosinolates is typically below 0.1 mmol/kg, and only rarely amount to up to 0.2 mmol/kg, then the 
actual intake of glucosinolates would be considerably lower. 
According to the provided batch testing, AITC levels in the NF are below the limit of detection 
(1 mg/kg). EFSA has derived an acceptable daily intake (ADI) for allyl isothiocyanates of 20 µg/kg 
bw per day (EFSA, 2010a). A high daily intake by adults of 77 g of the NF with a 1 mg/kg AITC 
content would result in an intake of 77 µg or 1.1 µg/kg bw, far below the ADI established by EFSA. 
The Panel also notes the concentrations of AITC found in other foods such as horseradish (Armoracia 
lapathifolia) (1 500 – 9 000 mg/kg), Wasabi (Wasabi japonica, “Japanese horseradish”) (9 600 
mg/kg), cabbage (Brassica oleracea) (0.04-2.9 mg/kg) and cauliflower and broccoli (0.06 mg/kg) 
(TNO, 2009). Concentrations in mustard are also reported to vary considerably depending on the 
species of seed, ranging from 400-15 000 mg/kg (Velisek et al., 1995). 
The content of phytic acid of the NF ranges from 0.44-1.1 %. According to the data provided by the 
applicant, rapeseed and soybeans contain small and similar amounts of phytic acid. Phytic acid is 
known to reduce the bioavailability of minerals, if present in food or feed at a sufficient concentration 
(Kumar et al., 2010). Phytic acid is ingested with many plant-derived foods. Soy protein isolate is 
reported to contain 1.6-2.0 % phytic acid (Honig et al., 1984). Lower values (0.49-0.84 %) were 
reported more recently (Hurrell et al., 1992). In tofu, 1.46-2.90 % phytic acid was found (on a dry 
matter basis). Whole wheat bread contains 0.43-1.05 % phytic acid (on a dry matter basis) (Reddy et 
al., 2001). The Panel considers that the phytate concentration in the NF corresponds to that of 
commonly consumed foods. 
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The main phenolic substance present in rapeseed is 3,5-dimethoxy-4-hydroxycinnamic acid (sinapic 
acid). Sinapic acid occurs in rapeseed (and mustard seed) in free acid form, as well as in esterified 
form (esterified with choline or glucose) (Thiyam et al., 2006; Khattab et al., 2010). Analysis of 
sinapin, the choline ester of sinapic acid, revealed concentrations of 100-500 mg/kg in the NF. This is 
rather lower than the levels of sinapic acid alone found in apple, pear, broccoli, potato flour and other 
common foods (Manach et al., 2004; Robbins et al., 2005).  
Colorimetric analysis for total extractable phenolic compounds, which also include proanthocyanidins 
and extractable tannins, reveals contents of about 1-3 g/kg NF. These are levels that are commonly 
found in plant foods (on a dry matter basis) and which may result in daily intakes of 2.5 to 3 g/day for 
subjects consuming a Mediterranean diet (Saura-Calixto et al., 2007; Arranz et al., 2008). However, 
values of total phenolics vary depending upon the applied analytical method (Escarpa and González, 
2001). The colorimetric method applied for the analysis of the NF, i.e. the Folin-Ciocalteu method, 
gives, for example, a 3.6 times higher polyphenol content in dried lentils than analysis by HPLC 
(Escarpa and González, 2001). The lower daily intake of polyphenols which has been reported for 
Finnish adults (0.86 g/day) may, therefore, not be the result of a difference of dietary habits only, but 
also of the analytical method applied (HPLC) (Ovaskainen et al., 2008). Phenolic substances are also 
present in soybeans (2.1-3.4 g/kg), and consequently in soy protein isolates (Tepavčević et al., 2010). 
In soy beans, sinapic acid, p-coumaric acid, ferulic acid and p-hydroxybenzoic acid are found among 
other phenolic acids (Schmidt and Pokorny, 2005; Kim et al., 2006; Seo and Morr, 1984). Taken 
together, the same phenolic acids occur as secondary aromatic plant metabolites in rapeseed and soy 
bean protein isolates. The applicant acknowledges that there are quantitative and qualitative 
differences, but considers that these differences are not of toxicological concern because other plant-
derived foods contribute significant additional amounts to the total daily intake, and because some of 
these phenolic acids are also formed in and absorbed from the intestinal tract as microbial breakdown 
products of ingested flavonoids. 
The applicant has not carried out any toxicological studies on the NF. Instead, the applicant provided a 
teratogenicity, a sub-acute and two sub-chronic rat studies on rapeseed protein concentrates or isolates 
manufactured by other producers.  
No indication for teratogenicity was observed in a teratogenicity study with rats fed with a rapeseed 
protein concentrate which contained 0.2 mg glucosinolates/g protein concentrate (Sharpe et al., 1975).  
In a 28 day sub-chronic feeding study, rats received diets with 0, 2.5, 5.0 and 10 % rapeseed protein 
isolates (Plass et al., 1992). Increased absolute liver weights were observed in the 5 and 10 % diet 
groups.  
The Panel notes that the two studies do not provide sufficient information on the production and 
composition of the test preparations to allow conclusions to be drawn for the NF.  
The applicant also provided two articles on two 90-day toxicity studies in rats (20 rats/sex/group) 
which studied two rapeseed (canola quality) protein isolates produced by a competitor (Mejia et al., 
2009a, 2009b). One of the two protein isolates (Puratein
TM
) consists mainly of cruciferin (the globulin 
storage protein of rapeseed; > 80 % of the protein fraction), the remainder being the albumin storage 
protein napin (Mejia et al., 2009a). The other protein isolate (Supertein
TM
) consists mainly of napin 
(> 80 % of the protein fraction), the remainder being globulin (Mejia et al., 2009b). The protein 
composition of these two products differs from the NF with regard to both globulin and albumin 
fractions. Both products contain erucic acid, total glucosinolates, AITC, total phytates and phenolics at 
similar or higher concentrations than the NF. The two protein isolates were included in the test diets at 
levels of 0 (controls), 5, 10 and 20 %. A comparison group received a diet with 20 % casein. No test 
product-related effects on body weight, feed consumption, neurobehavioral and motor activity, or 
clinical chemical and hematological parameters were observed in rats fed diets with the cruciferin 
protein isolate (Mejia et al., 2009a). In contrast, rats fed diets with the napin protein isolate at 20 % 
consumed less feed than controls during most of the study, and the consumption was statistically 
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significantly lower during nine weeks in male rats and during three weeks in female rats. In the 10 % 
dose group, the feed intake was statistically lower during seven weeks for males and during two weeks 
for females, and in the 5 % dose group males had a statistically significant lower feed intake for three 
weeks (Mejia et al., 2009b).  
The lower food intake was associated with significantly lower cumulative body weight gains in males 
and females of the 20 % dose group and males of the 10 % dose group (starting the first week of the 
study) and a significantly lower feed efficiency in the 20 % dose group (males during weeks 1 and 
weeks 4 and 5; females in the first week). The authors considered this effect to be due to a lower 
palatability, and they performed a four days separate palatability and preference study that confirmed a 
preference for the diet containing casein compared to the napin protein isolate.  
However, the Panel notes that a low palatability effect is usually transient, and that a four day 
preference study performed and reported by Mejia et al. (2009b) does not allow exclusion of the 
possibility that the napin protein isolate produced discomfort which induced a conditioned taste 
aversion that durably reduced feed intake, as observed in the study. The observed effects on feed 
consumption and feed efficiency were present already from the very onset of the exposure in week 1. 
No pathological effects were observed by the analyses of haematology, coagulation and clinical 
chemistry parameters, and opthamological and histopathological examinations of organs and tissues 
did not reveal any treatment-related changes.  
Organ weights were not affected by the treatment with the possible exception of the relative thyroid 
plus parathyroid weight, which was slightly but significantly increased in females, but not males, of 
the high dose napin protein isolate group (Mejia et al,. 2009b) and in both sexes of the high dose 
cruciferin protein isolate group (Mejia et al., 2009a). In the absence of histopathological changes of 
the thyroids, the Panel considered that the increases in thyroid weight were not of toxicological 
relevance.  
The Panel considers that in the study with cruciferin protein isolate, no treatment-related effects were 
noted, whereas in the study with napin protein isolate lower feed intake associated with reduced body 
weight gain and a reduced feed efficiency was observed, which may be caused by a low palatability 
and in part by an antinutritional effect inducing discomfort and consequently a conditioned taste 
aversion. 
The Panel notes that, although both products studied by Mejia et al. (2009a, b) are not identical to the 
NF, the composition of cruciferin protein isolate, which did not show any adverse effect (Mejia et al., 
2009a), was more similar to the NF than the napin protein isolate (Mejia et al., 2009b).  
9. ALLERGENICITY 
Several Member States expressed concerns with regard to a potential risk of allergenicity of rapeseed 
proteins in general, and with regard to potential cross-allergenicity of rapeseed proteins with proteins 
of other Brassicacae, particularly of mustard. 
To date, rapeseed has been used as a food in the EU only in the form of rapeseed oil, which normally 
contains only traces of rapeseed protein. Foods with a higher content of rapeseed protein have not 
been consumed in significant quantities. The applicant has not carried out any studies to determine the 
potential allergenicity of the NF.  
Food allergy to rapeseed (Brassica rapa L.) and oilseed rape (Brassica napus L.) has been reported to 
occur, as evidenced by studies by Puumalainen et al. (2006), Poikonen et al. (2006) and Poikonen et 
al. (2008). In the study by Poikonen et al. (2006), 11 % (206/1 887) of atopic Finnish children with 
suspected food allergies who were screened using skin prick tests showed sensitivity to seeds of 
Brassica rapa L. and/or Brassica napus L. In a subsequent challenge test 89 % of these sensitised 
children reacted to rapeseed. In parallel, a group of homologous proteins, 2S albumins or napins, were 
identified as new possible food allergens (Puumalainen et al., 2006). The authors considered that even 
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the smallest quantities of protein residues present in refined or cold-pressed rapeseed oils might be 
sufficient to produce sensitisation. Monsalve et al. (1997) identified 2S storage proteins ('napins') in 
Brassica napus L. seeds which may cause allergic reactions by aerogen exposure. BnIII napin, which 
accounts for 30 % of all napins occurring in Brassica napus L., was identified as the major allergen. 
Napins consist of a small and large chain linked by disulfide bonds (Lönnerdahl and Janson, 1972) and 
are extremely resistant to pepsin digestion and denaturation caused by heat and low pH (Murtagh et 
al., 2003). Napins represent approximately 20 % of the total protein of the seeds, and according to the 
applicant about one third of the NF. 
There are also indications of cross reactivity between rapeseed and other foods. Several authors have 
previously reported on cross reactivity between the proteins of rape and mustard seeds (Meding 1985, 
Widstrom and Johansson 1986, Monreal et al., 1992). Monsalve et al. (1997) demonstrated IgE and 
IgG cross-reactivity between BnIII napin and Sin a1, the major allergen in seeds of the Brassica alba 
L. plant used in the production of yellow mustard, by inhibition ELISA. Mustard allergy has been 
reported in France, and has been investigated also in Spain, including studies on cross-reactions within 
Brassicaceae (Rance, 2003, Figueroa et al, 2005). Recombinant rapeseed 2S pronapin precursor 
protein was found to bind IgE in sera from mustard (Sin a 1) allergic patients as well as IgE in serum 
from a rapeseed allergic patient (Palomares et al., 2002). Seed storage proteins of various members of 
Brassicaceae, including mustard, have highly homologous molecular level structures with up to 94 % 
sequence similarity, and present risks of allergic reactions and cross-reactions in sensitised individuals 
(Monsalve et al., 2001;  Poikonen et al., 2009).  
The applicant proposed to inform individuals with mustard allergy about the potential unsuitability of 
foods formulated with canola protein isolate for their consumption. 
The Panel considers that the risk of sensitisation to rapeseed cannot be excluded and that it is likely 
that rapeseed trigger can allergic reactions in mustard allergic subjects.  
DISCUSSION 
While canola oil has a pre-1997 history of safe food use, canola protein isolates have not been 
consumed in the EU in significant quantities. The presence of antinutritive substances in rapeseed (i.e. 
erucic acid, phytic acid and glucosinolates) previously limited the potential of rapeseed as a source of 
protein for food and feed. With the introduction of rapeseed cultivars with a naturally low content of 
erucic acid and glucosinolates (canola quality), this protein source has become potentially fit for 
human consumption. The rapeseed proteins can now be isolated with conventional separation 
techniques from the press cake (rapeseed meal), and purified up to the level of protein isolates (> 90 % 
protein). According to data provided by the applicant, the levels of undesirable compounds contained 
in the NF, such as erucic acid, glucosinolates and phytates, are either below detection limits or below 
levels which raise concerns.  
The Panel considers that the information provided on the manufacturing process, as well as on the 
composition, specification and nutritional value of the NF, is sufficient and does not raise safety 
concerns. 
The NF, a canola quality rapeseed protein isolate, shares many properties with soy protein isolates, 
which are isolated in a similar way from the press cake remaining from soy oil production. The 
macronutrient composition of the NF is similar to commercially available soy protein isolates. The 
biological value of rapeseed and soy protein, determined by the PDCAAS, appears to be similar. 
The Panel notes that in one 13-week rat study with cruciferin protein isolate, no treatment-related 
effects were noted, whereas in the study with napin protein isolate lower feed intake associated with 
reduced body weight gain and a reduced feed efficiency was observed, which may have been caused 
by a low palatability and in part by an antinutritional effect inducing discomfort. 
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The Panel notes that people may consume up to 2.2 g protein/kg bw per day, of which a significant 
part may come from rapeseed protein. The Panel also notes that some subgroups of the population, 
such as sportspeople, may consume even higher amounts of protein. Only in an extreme scenario, in 
which “high consumers”, such as vegans would consume rapeseed protein isolates as their sole source 
of protein, can an antinutritional effect not be excluded. The Panel considers that such a worst case 
scenario is unrealistic, and it would imply the consumption of an unbalanced diet, which is generally 
not recommended.  
The Panel considers that the risk of sensitisation to rapeseed cannot be excluded and that it is likely 
that rapeseed trigger can allergic reactions in mustard allergic subjects.  
The Panel notes the source and nature of the novel food, the absence of a nutritional disadvantage at 
the proposed uses and use levels, the low concentrations of potentially adverse components in the NF, 
the extended use of rapeseed press cake in farm animals, and the absence of toxicologically relevant 
effects in subchronic studies with rats of other rapeseed protein isolates with similar compositions. 
The Panel notes that based on the results of one of the rat studies, the possibility of an antinutritional 
effect caused by the novel food at high intakes, i.e. if rapeseed protein isolate was the main protein 
source in the diet, cannot be excluded.  
CONCLUSIONS 
The Panel concludes that rapeseed protein isolate is safe under the proposed uses and use levels. 
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4. Member States‟ comments and objections. 
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APPENDIX 
Analytical results from testing of twelve batches  
Component (unit) Specifications 
Limit of 
detection 
Typical 
contents (a) 
BBl10004 
(b) 
BBl10007 
(b) 
BBl10008 
(b) 
BBl10009 
(b) 
BIOEXX 
20120109 (a) 
BIOEXX 
20120110 (a) 
BIOEXX 
20120213 (a) 
BIOEXX 
20120214 (a) 
BIOEXX 
20120215 (a) 
BIOEXX 
20120221 (a) 
BIOEXX 
20120227 (a) 
BIOEXX 
20120313 (a) 
Protein (%) (c) ≥ 90 % n. s. 92.7 95.3 91.7 90.7 93.3 92.2 91.9 90.7 92.7 96.6 89.7 91.6 91.2 
Solubility (%) n. s. n. s. n.s. 99 97 97 96 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Pass through 
US 80 mesh (%) 
> 90 % n. a. n.s. 95 95 95 95 95 95 94 94 94 90 89 74 
Moisture (%) ≤ 7 % n. s. 3.7 3.3 3.7 3.2 1.5 5.04 5.4 4.95 4.75 5.08 4.65 4.47 5.88 
Fat (%) direct (d) n. s. n. s. ≤ 0.5 0.26 0.23 0.22 0.13 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Fat (%) total (e) < 2 % n. s. 1.8 n. a. 1.7 n. a. n. a. 1.28 0.72 0.79 0.71 0.34 1.74 1.09 0.6 
Fibre (%) ≤ 0.5 % n. s. < 0.1 0.0 < 0.02 0.06 0.05 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Ash (%) ≤ 4 % n. s. 2.3 2.2 2.0 2.3 2.3 2.4 2.68 2.4 2.7 1.3 1.4 1.48 1.20 
Carbohydrates (%) (f) ≤ 7 % n. s. 4.1 2.2 6.1 6.7 4.2 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Na (ppm) n. s. n. s. 660 550 246 200 170 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
K (ppm) n. s. n. s. 430 420 291 530 280 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Ca (ppm) n. s. n. s. 3 810 4 100 4 160 3 850 4 070 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
P (ppm) n. s. n. s. 4300 3600 4500 4500 4 700 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Fe (ppm) n. s. n. s. 85 84 83 75 80 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Mg (ppm) n. s. n. s. 1 500 1 600 1 780 1 870 1 860 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Zn (ppm) n. s. n. s. 52 49 49 50 57 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Pb (ppm) ≤ 0.5 mg/kg n. s. < 0.01 0.02 0.02 0.02 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
As (ppm) n. s ≤ 0.05 n. s ≤ 0.05 ≤ 0.05 ≤ 0.05 ≤ 0.05 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Cd (ppm) n. s. n. s. n. s. 0.28 0.19 0.25 0.16 n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Al (ppm) n. s. n. s. n. s. 7.6 12 9.2 7.5(l) n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
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Abbreviations: cfu = colony forming units, n. a. = not available, n. d. = not detected, n. s. = not specified, neg. = negative 
(a): Provided by BioExx Proteins of Saskatoon Inc., Canada 
(b): Analysed by POS Pilot Plants Saskatoon SK, Canada 
(c): Based on dry matter 
(d): Free fat measured by direct extraction with ether 
(e): Total fat measured by HCl hydrolysis followed by ether extraction 
(f) : Calculated by difference. Values are overestimates since for fat only values for extractable rather than total fat are available. 
(g): Provided by Eurofins 
(h): Analyses by Eurofins of Isolexx (dated 13/03/09 and 03/06/10) 
(i): GC-MS analyses by Eurofins of Isolexx (dated 02/08/2011) 
(j): Analysis by University of Nebraska Lincoln (dated 04/06/2011)  
(k): Analyses by University of Saskatoon 
(l): Misreported as 75 in initial application dossier 
Erucic acid 
(% of total fat) 
n. s. 0.1(a, g) n. d. (h) n. a. n. a. n. a. n. a. 
n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Total glucosinolates 
(mmol/kg) 
≤ 1 0.1(g) ≤ 0.1 n. a. n. d. n. d. n. d. 
n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Allyl isothiocyanate 
(mg/kg) 
n. s. 1(g, i) n. d. n. d. n. d. n. d. n. d. 
n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Total phytates 
(g/100 g) 
≤ 1.5 0.4(g) ≤ 1 0.44 0.83 1.14 1.03 
n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Phenolics 
(total in gallic acid 
equivalents) (g/kg) 
n. s. 0.05(j) < 2 n. a. 1.53(k) 1.52(k) 1.12(k) 
n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Sinapin 
(mg/kg) 
n. s. 50(a) ≤ 500 200(j) 180(j) 80(j) n. a. 
n. a. n. a. n. a. n. a. n. a. n. a. n. a. n. a. 
Aerobic bacteria count ≤ 10 000 cfu/g < 5 n. s. 410 80 6 700 9 800 460 9 000 3 300 630 300 1 800 300 1 800 
E. coli (cfu) neg./10 g < 5 neg. neg. < 5 < 5 < 5 neg. neg. neg. neg. neg. neg. neg. neg. 
Salmonella (cfu) neg./25 g < 5 neg. neg. neg. neg. neg. neg. neg. neg. neg. neg. neg. neg. neg. 
Yeast and mold counts 
(cfu /g) 
100 < 5 n. s. 120 < 5 < 5 280 10 10 10 10 10 10 10 10 
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ABBREVIATIONS 
ADI  Acceptable daily intake 
AITC  Allyl isothiocyanates 
Bw  Body weight 
Cfu  Colony forming unit 
FTU  Phytase unit 
GLP  Good Laboratory Practice  
GMP  Good Manufacturing Practice 
GM(O)  Genetic Modification/Modified (organism)  
GRAS  Generally recognized as safe 
IOM  Institute of Medicine 
kDa  kiloDaltons 
NF(I)  Novel Food (Ingredient) 
NMR  Nuclear Magnetic Resonance 
NOAEL  No Observed-Adverse-Effect Level  
PDCAAS Protein-digestibility corrected amino acid 
SCF  Scientific Committee on Food  
